Claims:

[Claim 1]. An antibody or antigen binding fragment which is capable of binding to TIM-3, optionally isolated, having the amino acid sequences i) to vi):

i)	LC-CDR1:	RASQSVGSYLA	(SEQ ID NO:9)
ii)	LC-CDR2:	DATNRAT	(SEQ ID NO:10)
iii)	LC-CDR3:	QHRRT	(SEQ ID NO:11)
iv)	HC-CDR1:	SSDYYWG	(SEQ ID NO:59), or
		GGSIGSSDYYWG	(SEQ ID NO:27)
v)	HC-CDR2:	SIYYSGSTYYNPSLKS	(SEQ ID NO:28)
vi)	HC-CDR3:	GEHRGEFDY	(SEQ ID NO:29).

[Claim 2]. The antibody or antigen binding fragment of claim 1, comprising a heavy chain and a light chain variable region sequence, wherein:

the heavy chain sequence has at least 70% sequence identity to the heavy chain sequence of SEQ ID NO:20, and

the light chain sequence has at least 70% sequence identity to the light chain sequence of SEQ ID NO:2.

[Claim 3]. The antibody, or antigen binding fragment, of any one of claims 1 or 2, wherein the antibody is effective to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

[Claim 4]. An antibody or antigen binding fragment, optionally isolated, which is capable of binding to TIM-3, which is a bispecific antibody or a bispecific antigen binding fragment comprising (i) an antigen binding fragment or polypeptide according to any of one of claims 1 to 3, and (ii) an antigen binding domain which is capable of binding to a target protein other than TIM-3.

[Claim 5]. The antibody, or antigen binding fragment, of claim 4, wherein the antigen binding domain which is capable of binding to a target protein other than TIM-3 is capable of binding to CD3 or a CD3 polypeptide.

[Claim 6]. An *in vitro* complex, optionally isolated, comprising an antibody, or antigen binding fragment, according to any one of claims 1 to 5 bound to TIM-3.

[Claim 7]. A composition comprising the antibody or antigen binding fragment of any one of claims 1 to 5 and at least one pharmaceutically-acceptable carrier.

[Claim 8]. An isolated nucleic acid encoding the antibody or antigen binding fragment of any of one of claims 1 to 5.

[Claim 9]. A vector comprising the nucleic acid of claim 8.

[Claim 10]. A host cell comprising the vector of claim 9.

[Claim 11]. A method for making an antibody, or antigen binding fragment or polypeptide of any of one of claims 1 to 5 comprising culturing the host cell of claim ~~11~~ 10 under conditions suitable for the expression of a vector encoding the antibody, or antigen binding fragment or polypeptide, and recovering the antibody, or antigen binding fragment or polypeptide.

[Claim 12]. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in therapy, or in a method of medical treatment.

~~[Claim 13]. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in the treatment of cancer or a T-cell dysfunctional disorder.~~

[Claim ~~14~~13]. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in the treatment of cancer.

[Claim ~~15~~14]. An antibody or antigen binding fragment according to any of one of claims 1 to 5 for use in the treatment of an infectious disease.

~~[Claim 16]. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 5 in the manufacture of a medicament for use in the treatment of cancer or a T-cell dysfunctional disorder.~~

[Claim 17]15]. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 5 in the manufacture of a medicament for use in the treatment of cancer.

[Claim 18]16]. Use of an antibody or antigen binding fragment according to any of one of claims 1 to 5 in the manufacture of a medicament for use in the treatment of an infectious disease.

[Claim 19]. A method, *in vitro*, of enhancing T-cell function comprising administering an antibody or antigen binding fragment according to any one of claims 1 to 5 to a dysfunctional T-cell.

[Claim 20]17. A method comprising contacting a sample containing, or suspected to contain, TIM-3 with an antibody or antigen binding fragment according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

[Claim 21]18. A method of diagnosing a disease or condition in a subject, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

[Claim 22]19. A method of selecting or stratifying a subject for treatment with a modulator of TIM-3 signalling, the method comprising contacting, *in vitro*, a sample from the subject with an antibody, or antigen binding fragment, according to any one of claims 1 to 5 and detecting the formation of a complex of antibody, or antigen binding fragment, and TIM-3.

[Claim 23]20]. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 5 for the detection of TIM-3 *in vitro*.

[Claim 24]21]. Use of an antibody, or antigen binding fragment, according to any one of claims 1 to 5 as an *in vitro* diagnostic agent.

[Claim 25]22]. A method for expanding a population of T cells, wherein T cells are contacted *in vitro* or ex vivo with an antibody or antigen binding fragment according to any one of claims 1 to 5.